1
All patients with TRAPS were primarily treated with etanercept and all CAPS patients with canakinumab.
2
Methods: Clinical responses of 70 patients treated with etanercept were determined according to the ACR criteria.
3
We report the case of a patient with long-standing moderate to severe psoriasis who developed acute hepatitis C while being treated with etanercept.